Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients

Gannagé‐Yared, Marie‐Hélène; Azar, Rabih R.; Amm-Azar, Mireille; Khalife, Simon; Germanos-Haddad, Myrna; Neemtallah, Ramy; Halaby, Georges

doi:10.1016/j.metabol.2005.02.011

Cited by 73 publications

(55 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, its administration for 8 w in human suffering of obesity and T2DM reduced plasma leptin concentrations by 40%. It was reported ATV, pitavastatin and pravastatin elevated the serum adiponectin concentrations, and elevated plasma adiponectin levels in hypercholesterolemic human [37] .…”

Section: Resultsmentioning

confidence: 90%

Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs

Rasheed¹,

Abdelkarem²,

Laila³

et al. 2016

pharmaceutical-sciences

View full text Add to dashboard Cite

Al-Rasheed, et al.: Amelioration of Insulin, Leptin and AdiponectinA comparative study was planned to explore the modulating impact of metformin, Lipitor or orlistat against the metabolic syndrome components, including hyperglycemia and hyperlipidemia. Also, the effects of these drugs on leptin and adiponectin as biomarkers of metabolic syndrome in a rat model were investigated for the first time. The administration of these drugs each alone to metabolic syndrome induced rats markedly ameliorated the increase in blood glucose, normalized the serum insulin and the high-density lipoprotein cholesterol levels and reduced triglyceride, total cholesterol and low-density lipoprotein cholesterol. The alterations in serum leptin and adiponectin levels in metabolic syndrome induced rats were significantly modulated by these drugs. Metformin was the most effective drug in modulating most of the studied parameters.

show abstract

Section: Resultsmentioning

confidence: 90%

Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs

Rasheed¹,

Abdelkarem²,

Laila³

et al. 2016

pharmaceutical-sciences

View full text Add to dashboard Cite

show abstract

“…38 Pravastatin does not affect the adiponectin levels in healthy nondiabetic patients. 39 In Japanese patients with CAD and hypercholesterolemia, 6 mo of treatment with Pravastatin 10 to 20 mg/d was associated with significant increases in serum adiponecitn concentrations. 40 Fluvastatin does not improve plasma adiponectin levels, despite its beneficial effects on lipid levels.…”

Section: Discussionmentioning

confidence: 98%

Atorvastatin Administration after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease and Normal Lipid Profiles: Impact on Plasma Adiponectin Level

Chan

Chou

Huang

et al. 2008

Clinical Cardiology

View full text Add to dashboard Cite

Background: There is controversy about the effects of statins on plasma adiponectin, and the impact of percutaneous coronary intervention (PCI) on plasma adiponectin level is still unknown. We investigated the impact of Atorvastatin on plasma adiponectin levels in coronary artery disease (CAD) patients with stable angina and normal lipid profiles after PCI. Methods: Sixty CAD patients with stable angina and normal lipid profiles scheduled for PCI, and not on statins, were randomly assigned to either no treatment (control group) or the Atorvastatin treatment (Atorvastatin group). Atorvastatin administration was started immediately after PCI. Blood samples were obtained immediately after PCI and again 3 and 6 mo later. Fasting plasma adiponectin concentrations were measured using a radioimmunoassay kit. Results: After PCI, there were statistically significant decreases in adiponectin levels in the Atorvastatin group at 3 and 6 mo (8.66±0.69 versus 6.87±0.55 and 7.12±0.71 µg/mL at 0, 3, and 6 mo, respectively), despite the anti-inflammation and lipid-lowering effects of Atorvastatin. There were no statistically significant changes in adiponectin levels in the control group. There was significant positive association between baseline plasma adiponectin and high-density lipoprotein (HDL) levels. Changes of adiponectin level were not associated with the changes of high-sensitivity C-reactive protein (hs-CRP) and lipid profiles in the Atorvastatin group. Conclusions: Our study confirmed the benefits of Atorvastatin on anti-inflammation and anti-atherosclerosis, but we also found that Atorvastatin had a negative effect on the adiponectin system. The anti-inflammatory, anti-atherogenic effects of Atorvastatin are not affected by decreased adiponectin levels.

show abstract

“…Moreover, 8 wk of ator vastatin treatment (40 mg/d) in obese humans with T2DM reduced plasma leptin concentrations by 40% [16,20] . However, 12 wk of pravastatin treatment (40 mg/d) in humans with normal cholesterol concentrations had no effect on serum leptin concentrations (Table 1) [21] . These data support the notion that the additional benefits of statins on circulating leptin require a pathophysiological elevation in blood lipids or leptin.…”

Section: Leptinmentioning

confidence: 99%

“…Additional studies utilizing simvastatin [74] , pravastatin [21] , fluvastatin [91] or atorvastatin [92][93][94] in a variety of subjects (healthy humans, humans with hypercholesterolemia or hyperlipoproteinemia or kidney transplant recipients) all found no change in circulating adiponectin concentrations in response to statin treatment. A possible explanation for this discrepancy may involve the analysis of the different multimers of adiponectin.…”

Section: Adiponectinmentioning

confidence: 99%

“…In Wistar rats treated with gemfibrozil (75 mg/kg per day) for 28 d, a significant decrease in serum leptin concentrations was observed in rats on a high-fat diet (P < 0.01), but not on a standard Leptin decreased by 38% from 8.9 ± 2.3 to 5.5 ± 2.8 µg/mL (P < 0.05) [20] Humans with T2DM Leptin decreased by 40% from 20.7 ± 2.3 to 12.5 ± 1.1 ng/mL. Resistin decreased by 20% from 3.5 ± 0.4 to 2.9 ± 0.4 µg/mL [95] Healthy humans 12 wk of pravastatin (40 mg/d) No changes in adiponectin or leptin [21] Humans with hypercholesterolemia 4 mo of pravastatin or atorvastatin (10 mg/d) Adiponectin increased from 10.7 ± 4.7 to 11.0 ± 5.1 µg/mL in response to atorvastatin (P < 0.05). No change in leptin or resistin.…”

Section: Leptinmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Wanders

Plaisance²,

Judd³

2010

WJD

View full text Add to dashboard Cite

The cardioprotective effects of lipid-lowering drugs have been primarily attributed to their effects on blood lipid metabolism. However, emerging evidence indicates that lipid-lowering drugs also modulate the synthesis and secretion of adipose tissue-secreted proteins referred to as adipokines. Adipokines influence energy homeostasis and metabolism and have also been shown to modulate the vascular inflammatory cascade. The purpose of this review will be to examine the reported effects of commonly used lipid-lowering drugs (statins, fibrates, niacin and omega-3-fatty acids) on the circulating concentrations of leptin, adiponectin, tumor necrosisfactor-α (TNF-α), Retinol binding protein 4 (RBP4) and resistin. Overall, the lipid-lowering drugs reviewed have minimal effects on leptin and resistin concentrations. Conversely, circulating adiponectin concentrations are consistently increased by each lipid-lowering drug reviewed with the greatest effects produced by niacin. Studies that have examined the effects of statins, niacin and omega-3-fatty acids on TNF-α demonstrate that these agents have little effect on circulating TNF-α concentrations. Niacin and fibrates appear to lower RBP4 but not resistin concentrations. The results of the available studies suggest that a strong relationship exists between pharmacological reductions in blood lipids and adiponectin that is not obvious for other adipokines reviewed.

show abstract

Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients

Cited by 73 publications

References 30 publications

Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs

Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs

Atorvastatin Administration after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease and Normal Lipid Profiles: Impact on Plasma Adiponectin Level

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Contact Info

Product

Resources

About